Careers  |  Sign In  |  Register

Dr. Daver on the Utility of Maintenance Therapy in AML

Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses maintenance chemotherapy in acute myeloid leukemia (AML). Dr. Daver points to the May 2020 FDA priority review designation for oral azacitidine (CC-486) as maintenance therapy in patients with AML who were not receiving hematopoietic stem cell transplants. The median overall survival of CC-486 recipients was 26 months compared to 15 months for the placebo group.

Click here to learn more.